Camlin Fine Sciences Ltd

- No mention of any immediate or significant new fundraising through debt or equity in the transcript. - The company completed a successful rights issue in January 2025, which increased equity and helped reduce net debt from INR 564 crores to INR 492 crores. - Currently, there is no indication of plans for major capex or large fund-raising initiatives; the focus is on sweating existing assets, especially the vanillin plant. - Maintenance and some small debottlenecking capex are planned, but no significant capital expenditure requiring new funding is anticipated. - Management's remarks suggest maintaining current financial stability and focusing on growth without new large-scale fundraising for the near term.

- Currently, Camlin Fine Sciences is not planning any significant capital expenditure. - The focus is on optimizing and "sweating" the vanillin plant rather than new large investments. - Only maintenance capex and some minor debottlenecking activities are anticipated. - There is no mention of new strategic investments or major capex projects for the near future. - The company is currently prioritizing operational efficiency before considering further expansion.

- Blends business expected to grow approximately 20% annually over the next 2-3 years, with EBITDA margins moving towards high teens and potentially nearing 20% as the business matures. - Aroma business to continue momentum with anticipated revenue increase fueled by anti-dumping duties in the U.S. and EU, supporting price rises. - Vanillin business expected to ramp up to 100% capacity utilization over the next 2 years, with volume growth anticipated in U.S. and European markets due to anti-dumping duties favoring domestic producers. - Total core business has grown about 15% year-on-year, with healthy volume growth in blends, especially in North America and India. - The Vinpai acquisition (expected to close by July) is projected to add significant growth potential, potentially lifting overall growth from 20% to around 25%. - Market expansion is broad-based across geographies including North and Central America, Europe, Middle East, Africa, and Asia.

- Blends business expected to grow around 20% annually over the next 2-3 years, with EBITDA margins in the high teens advancing towards 20%. - Total blended business revenue to rise from INR878 crores currently with a 20% CAGR for the next 2 years. - Vanillin plant utilization targeted to reach 100% within 2 years, driving volume growth. - Aroma business revenue at INR176 crores in FY'25 expected to ramp up further, supported by anti-dumping duties in the U.S. and EU. - Overall core business grew 15% YoY with stabilized margins around 12.5% EBITDA. - Discontinued operations’ cash burn expected to reduce significantly, improving net profitability. - Growth momentum supported by expanding markets in North America, India, Latin America, Europe, Middle East, and Africa. - No significant capex planned currently, focusing on sweating existing assets for margin improvement.

- Nirmal Momaya mentioned there are very good conversations and contracts being negotiated in the pipeline, particularly related to aroma and blend businesses. - For vanillin, major players including Solvay and Camlin are actively pursuing contract negotiations in the U.S. and Europe. - The anti-dumping duty approvals in the U.S. and Europe are expected to result in volume growth over the next 3 to 4 quarters. - No specific quantitative order book or pending orders figures were disclosed. - The management indicated cautious volume commitments due to existing customer inventories and ongoing price negotiations. - For the Lockheed Martin business, no orders or timelines are yet available, as the first battery installation is still under feedback evaluation. - Overall, the discussions suggest a healthy but cautiously managed order pipeline, expecting stronger volume visibility in the coming months after regulatory clarity.